Dataset Viewer
Auto-converted to Parquet Duplicate
id
int64
1.17M
2.23M
trial_nct_id
stringlengths
11
11
description
stringlengths
1
300
label
stringlengths
1
101
type
stringclasses
6 values
1,173,743
NCT07169825
null
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA
EXPERIMENTAL
1,173,744
NCT01153542
null
VX-770
EXPERIMENTAL
1,173,745
NCT01153542
null
desipramine
EXPERIMENTAL
1,173,746
NCT03169374
Virtual Reality Therapy
Virtual Reality Technology
EXPERIMENTAL
1,173,747
NCT02730169
BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
BGS649 0.1 mg
EXPERIMENTAL
1,173,748
NCT02730169
BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
BGS649 0.3 mg
EXPERIMENTAL
1,173,749
NCT02730169
BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
BGS649 1.0 mg
EXPERIMENTAL
1,173,750
NCT02730169
Placebo weekly (3 indistinguishable placebo capsules)
Placebo
PLACEBO_COMPARATOR
1,173,751
NCT03885206
Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
Hospital
EXPERIMENTAL
1,173,752
NCT03885206
Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
Municipal acute ward
NO_INTERVENTION
1,173,753
NCT03076164
Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
Trametinib 1.5mg + Erlotinib 75mg
EXPERIMENTAL
1,173,754
NCT04250844
We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy with intrapyloric botulinum injections and if clinically applicable endoscopic functi
Botulinum
null
1,173,755
NCT04250844
We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy without intrapyloric botulinum injections.
Control
null
1,173,756
NCT01100580
"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
water therapy
ACTIVE_COMPARATOR
1,173,757
NCT01100580
low salt diet refers to a salt intake of 4 g/day
low salt diet + water therapy
EXPERIMENTAL
1,173,758
NCT02571881
Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
Oxycodone
ACTIVE_COMPARATOR
1,173,759
NCT02571881
Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
Oxycodone-naloxone
EXPERIMENTAL
1,173,760
NCT03796130
"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomlyallocated intotwo groups.~In group (A): myomectomy will be performed before ART~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months
(A)Myomectomy
EXPERIMENTAL
1,173,761
NCT03796130
"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (B):women will have their trial of ART without myomectomy"
(B) No myomectomy
NO_INTERVENTION
1,173,762
NCT04574505
1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks
NUT
EXPERIMENTAL
1,173,763
NCT04574505
1 tablet of Placebo per day + standard diet for 8 weeks
Placebo
PLACEBO_COMPARATOR
1,173,764
NCT02117154
6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart
HbA1c, 6-day Professional CGM
null
1,173,765
NCT01622335
General anesthesia and Air
General anesthesia with oxygen
PLACEBO_COMPARATOR
1,173,766
NCT01622335
General anesthesia with Nitrous Oxide
nitrous oxide and general anesthesia
EXPERIMENTAL
1,173,767
NCT06833801
Participants in this group will receive an optimized intelligent care system designed to enhance patient safety, improve treatment adherence, and reduce anxiety during radiation therapy. This system includes real-time blood data monitoring alerts, enhanced patient education materials, and internal w
Intelligent Care System Group (Intervention Group)
EXPERIMENTAL
1,173,768
NCT06348212
They are given probiotic capsules of Lactobacillus paracasei PS23. Each capsule contains 100 mg of probiotic powder(10,000,000,000 CFU) Subjects should take two capsules per day for two months
Probiotic group
EXPERIMENTAL
1,173,769
NCT06348212
They are given probiotic capsules of microcrystalline cellulose. Subjects should take two capsules per day for two months
Placebo group
PLACEBO_COMPARATOR
1,173,770
NCT05826158
null
Children with Neuroblastoma
OTHER
1,173,771
NCT05504083
take D-0120 dose 1 orally during the treatment period.
D-0120 group 1
EXPERIMENTAL
1,173,772
NCT05504083
take D-0120 dose 2 orally during the treatment period.
D-0120 group 2
EXPERIMENTAL
1,173,773
NCT05504083
take benzbromarone orally during the treatment period.
Benzbromarone
ACTIVE_COMPARATOR
1,173,774
NCT06833801
Participants in this group will receive standard care without the optimized intelligent care system interventions. They will continue their treatment following existing clinical practices without additional automated monitoring or enhanced education strategies.
Standard Care Group (Control Group)
NO_INTERVENTION
1,173,775
NCT06787885
Tavanic (levofloxacin )and dalacin (clindamycin)
Patient with empyema
OTHER
1,173,776
NCT06787885
Tavanic (levofloxacin) and cefipime
Empyema patient
OTHER
1,173,777
NCT06787885
Moxiflox (moxifloxacin) and meronem
patient has lung empyema
OTHER
1,173,778
NCT03842826
Male athletes performing sports ≥ 1x/week Age: 18-40 years
Athlete
null
1,173,779
NCT06778148
Providers assigned a license
Assigned Abridge license
EXPERIMENTAL
1,173,780
NCT06776367
In-clinic study visits and clinic-collected specimens
Group A
null
1,173,781
NCT05504083
take D-0120 dose 3 orally during the treatment period.
D-0120 group 3
EXPERIMENTAL
1,173,782
NCT02398474
Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
iliac crest bone graft with a TFP block
EXPERIMENTAL
1,173,783
NCT02398474
RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
local anesthetic infiltration of the surgical site.
ACTIVE_COMPARATOR
1,173,784
NCT07172451
Patients randomized to the balanced gelatin group will receive balanced gelatin solution (4% succinylated gelatin in a balanced crystalloid carrier) as the primary resuscitation fluid during emergency abdominal surgery for sepsis. Fluid administration follows a goal-directed protocol guided by strok
Balanced Gelatin Solution
EXPERIMENTAL
1,173,785
NCT07172451
Patients randomized to the crystalloid group will receive acetate Ringer's solution as the sole resuscitation fluid during emergency abdominal surgery for sepsis, according to the same goal-directed protocol guided by stroke volume monitoring. No gelatin solution will be administered in this group.
Crystalloid Solution
ACTIVE_COMPARATOR
1,173,786
NCT07167966
Intravenous infusions of anti-amyloid mAb-matched placebo for 6 months, followed by subcutaneous injections of AADvac1 over 24 months (n = 150)
AADvac1 monotherapy
EXPERIMENTAL
1,173,787
NCT07167966
Intravenous infusions of an anti-amyloid mAb for 6 months, combination anti-amyloid mAb and subcutaneous injections of AADvac1 for 6 months, followed by 18 months of AADvac1 injections alone (n = 150)
Combination AADvac1 therapy with anti-amyloid monoclonal antibody (mAb)
EXPERIMENTAL
1,173,788
NCT07167966
Intravenous infusions of an anti-amyloid mAb for 6 months, combination anti-amyloid mAb and AADvac1-matched placebo subcutaneous injections for 6 months, followed by 18 months of AADvac1-matched placebo injections alone (n = 75).
Anti-amyloid monoclonal antibody (mAb) active control
ACTIVE_COMPARATOR
1,173,789
NCT06778148
Providers not assigned a license or waitlisted
Control
NO_INTERVENTION
1,173,790
NCT04598854
The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 \~ 3.0Mw, 60 minutes each time, on
Treatment group
EXPERIMENTAL
1,173,791
NCT04598854
The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
Control group
SHAM_COMPARATOR
1,173,792
NCT05636358
"The intervention includes existing home-based hypnotherapy self-exercises in MP3 format for a period of three months.~The intervention group of children with FAP or IBS in primary care receives the home-based hypnotherapy self exercises in addition to care as usual by their GP according to the guid
Home-based hypnotherapy
EXPERIMENTAL
1,173,793
NCT05636358
The control group of children with FAP or IBS in primary care will receive only care as usual by their GP. After the end of the study, the control group will also receive access to the home-based hypnotherapy exercises, if desired.
Control
NO_INTERVENTION
1,173,794
NCT06776367
Fully remote evaluation and self-collected specimens
Group B
null
1,173,795
NCT07174310
Participants will receive Prasinezumab as an IV infusion in the double blind treatment period. Upon completion, eligible participants will enter into the Open Label Extension (OLE) phase.
Prasinezumab
EXPERIMENTAL
1,173,796
NCT07174310
Participants will receive placebo as an IV Infusion.
Placebo
EXPERIMENTAL
1,173,797
NCT07176559
Eligible and consented patients randomly assigned to the spiritual care intervention will receive a total of 4 visits with a board-certified or board-eligible chaplain. The intervention will utilize the Spiritual Care Assessment and Intervention (SCAI) framework. These visits will occur weekly for a
Spiritual Care
EXPERIMENTAL
1,173,798
NCT07176559
Eligible and consented patients randomly assigned to the Informational Support comparator will receive 4 visits with a trained social worker. The comparator intervention will include discussion of topics including quality of life, financial resources, and evaluating health information. These visits
Informational Support
PLACEBO_COMPARATOR
1,173,799
NCT04325646
Subjects who had been to China in the weeks before the outbreak began
CORSER-1a
null
1,173,800
NCT06776458
Breast cancer patients at 1-year post-diagnosis, who were treated with aromatase inhibitors
Aromatase Inhibitors (1 year)
null
1,173,801
NCT06776458
Breast cancer patients at 5-year post-diagnosis, who were treated with aromatase inhibitors
Aromatase Inhibitors (5 year)
null
1,173,802
NCT06362369
Alintegimod dose escalation, 4 cohorts Alintegimod monotherapy 1 cycle Alintegimod + Ipilimumab - 4 cycles Nivolumab - 11 cycles
Dose Escalation - Open Label Phase 1b
EXPERIMENTAL
1,173,803
NCT07171905
null
investigating the role of CAIX as target in VHL disease and in VHL-/- tumors
EXPERIMENTAL
1,173,804
NCT07174440
Participants scheduled for spinal surgery will have ESP block medications administered as per standard care along with contrast dye.
Spinal Surgery Participants
EXPERIMENTAL
1,173,805
NCT07177885
Blood collection
Migraineurs responding to triptans
null
1,173,806
NCT07177885
Blood collection
Migraine sufferers resistant to triptans
null
1,173,807
NCT07180147
"Community-dwelling adults aged 50 and older who receive a comprehensive baseline and annual health assessment at the Marymount University Center for Optimal Aging. Assessments include physical, cognitive, and psychosocial measures. Results are compiled into a personalized Health Passport with tailo
ALOHA Health Passport Cohort
null
1,173,808
NCT07180550
Participants will perform a high-intensity interval training based on six sets of 2-minute runs at an intensity of 90-95% of the maximal aerobic speed (MAS) on a treadmill. The recovery between each set will be 2 minutes, during which the subject will walk at an intensity of 50-60% of MAS.
High-intensity interval training (running)
EXPERIMENTAL
1,173,809
NCT07180550
Participants will perform a high-intensity interval training based on six sets of 2-minute cycling will be performed at an intensity of 90-95% of the maximal heart rate on a stationary bike. The recovery between each set will be 2 minutes, during which the subject will cycle at an intensity of 50-60
High-intensity interval training (cycling)
EXPERIMENTAL
1,173,810
NCT04662632
Local antibiotic irrigation via the VT-X7 (Vancomycin and Tobramycin Exchanged over 7 Days) Treatment System adjuvant to two-stage exchange arthroplasty per standard of care.
Experimental
EXPERIMENTAL
1,173,811
NCT04662632
Standard of care for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer.
Control
ACTIVE_COMPARATOR
1,173,812
NCT02571543
"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.~Stage 2: 17 patients will be treated either with the lower dose of 400mg or
Intervention
EXPERIMENTAL
1,173,813
NCT02571543
The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examinat
Control
NO_INTERVENTION
1,173,814
NCT06776458
Breast cancer patients at 10-years post-diagnosis, who were treated with aromatase inhibitors
Aromatase Inhibitors (10 years)
null
1,173,815
NCT06776458
A woman without a history of cancer will be recruited to match each breast cancer patient will be matched on age and BMI (within 3 years and 3 kg/m2, whenever possible)
Matched Controls (1 year)
null
1,173,816
NCT07332546
Participants receive bilateral ultrasound-guided external oblique intercostal block (EOIB) (15 mL of the study local anesthetic mixture per side) in addition to standard general anesthesia and standardized postoperative analgesia (IV PCA butorphanol ).
EOIB Group
EXPERIMENTAL
1,173,817
NCT07332546
Participants do not receive any regional block. They receive standard general anesthesia and standardized postoperative analgesia only (IV PCA butorphanol).
Control Group
SHAM_COMPARATOR
1,173,818
NCT04325646
Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
CORSER-1b
null
1,173,819
NCT06776458
A woman without a history of cancer will be recruited to match each breast cancer patient will be matched on age and BMI (within 3 years and 3 kg/m2, whenever possible)
Matched Controls (5 years)
null
1,173,820
NCT06776458
A woman without a history of cancer will be recruited to match each breast cancer patient will be matched on age and BMI (within 3 years and 3 kg/m2, whenever possible)
Matched Controls (10 years)
null
1,173,821
NCT05548088
The subjects met the inclusion criteria, then collect the Lymphocytes and transfected with lentivirus to obtain LILRB4 STAR-T cells. The subjects were given fludarabine and cyclophosphamide chemotherapy 5 days before and 3 days after cell reinfusion. After two days of rest, the cells were reinjected
LILRB4 STAR-T cells
EXPERIMENTAL
1,173,822
NCT03684109
Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain.
IDH-Mutant Glioma Patients
EXPERIMENTAL
1,173,823
NCT06301997
ZAX.1400.P03, applied topically twice daily for 3 weeks after enrolment
Topical ZAX.1400.P03
EXPERIMENTAL
1,173,824
NCT06301997
Placebo, applied topically twice daily for 3 weeks after enrolment
Placebo
PLACEBO_COMPARATOR
1,173,825
NCT06465511
Patients randomized to the intervention arm will attend a 120-minute survivorship clinic in which each participant will be assessed by members of a multidisciplinary team comprising an oncology nurse practitioner, a dietitian, a cancer exercise specialist, and a counsellor.
Supportive clinic
EXPERIMENTAL
1,173,826
NCT06465511
Patients randomized to the control group will be given a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations.
Control: Self-management
ACTIVE_COMPARATOR
1,173,827
NCT05320432
Prior to the procedure, the patient will have two sets of two self-adhesive electrodes placed parallel to the spinal cord at the T10-L1 and S2-S4 levels for TENS administration. For participants randomized to the experimental group, the non-blinded study coordinator will turn on the TENS unit 5 minu
Transcutaneous electrical nerve stimulation (TENS)
EXPERIMENTAL
1,173,828
NCT05320432
For the participants randomized to sham, the same placement of electrodes will occur, but the unit will not be delivering electrical stimulation.
Sham
SHAM_COMPARATOR
1,173,829
NCT04823611
Placebo solution for subcutaneous injection.
Part A:Placebo
PLACEBO_COMPARATOR
1,173,830
NCT04823611
AZD8233 for subcutaneous injection.
Part A:AZD8233
EXPERIMENTAL
1,173,831
NCT04823611
Placebo solution for subcutaneous injection.
Part B:Placebo
PLACEBO_COMPARATOR
1,173,832
NCT04823611
AZD8233 medium dose for subcutaneous injection.
Part B:AZD8233 medium dose
EXPERIMENTAL
1,173,833
NCT04823611
AZD8233 low dose for subcutaneous injection.
Part B:AZD8233 low dose
EXPERIMENTAL
1,173,834
NCT04823611
Placebo solution for subcutaneous injection.
Part C: Placebo
PLACEBO_COMPARATOR
1,173,835
NCT04823611
AZD8233 medium dose for subcutaneous injection.
Part C: AZD8233 medium dose
EXPERIMENTAL
1,173,836
NCT04767568
"In Cohort A: 200 patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) OR with gross bleeding~In cohort B: 200 patients who have already performed colonoscopy candidates for surgery on their colorectal tumor"
Blood test
EXPERIMENTAL
1,173,837
NCT06300944
At the beginning of the operation, intravenous infusion of reifentanil 0.1\~0.2 μg/kg·min, propofol 2\~4mg/kg·h, rocuronium 0.3mg/kg·h intermittently, inhalation of 1%\~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate
Group C(Control Group)
ACTIVE_COMPARATOR
1,173,838
NCT01972555
Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
Minimally invasive aortic valve replacement
EXPERIMENTAL
1,173,839
NCT04325646
Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
CORSER-2a
null
1,173,840
NCT04634903
The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasiz
Supportive Therapy SSI (ST-SSI)
ACTIVE_COMPARATOR
1,173,841
NCT04634903
The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identif
Behavioral Activation SSI (BA-SSI)
EXPERIMENTAL
1,173,842
NCT04634903
"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study sum
Growth Mindset SSI (GM-SSI)
EXPERIMENTAL
End of preview. Expand in Data Studio

Clinical Trials Knowledge Graph

7,628,735 nodes. 15,531,427 edges. 575,778 clinical trials registered on ClinicalTrials.gov — with their arms, outcomes, sites, sponsors, conditions, interventions, MeSH codes and linked PubMed publications.

Built with Samyama Graph. Loader and ETL: samyama-ai/clinicaltrials-kg.

Stored as Parquet — 623 MB, against roughly 7 GB as raw JSON.

Attribution — required

Two acknowledgements travel with this data:

Courtesy of the U.S. National Library of Medicine.

Aggregate Analysis of ClinicalTrials.gov (AACT) Database. Clinical Trials Transformation Initiative (CTTI). Available at: https://aact.ctti-clinicaltrials.org/

Neither NLM nor CTTI endorses this dataset, its processing, or anything derived from it.

Licence

Registry data U.S. Government public domain (ClinicalTrials.gov, via AACT)
PubMed, MeSH NLM terms — no fees or royalties, commercial use permitted
Loader code Apache-2.0, in the GitHub repo. This does not govern the data.

license: other is used deliberately rather than a convenient SPDX tag. No single standard licence describes this: the underlying registry content is US Government material outside copyright, while NLM and CTTI both request attribution, which CC0 would wrongly imply is waived. The terms in full:

  • NLM (terms) — "No charges, usage fees or royalties"; reuse including commercial is permitted; you must acknowledge NLM, must not suggest NLM endorses your work, and must either track the current version or state that your copy may be outdated. This copy is a snapshot of 2026-04-02 and is not updated — see Limitations.
  • AACT / CTTI (site) — AACT is a daily reload of ClinicalTrials.gov: "Content is downloaded from ClinicalTrials.gov daily and loaded into AACT." CTTI states no licence and imposes no restriction, "encourages the use of all materials", and asks that the source be acknowledged, supplying the citation above.

What we checked, and what we did not. Both sets of terms above were read directly at source. Neither prohibits redistribution. CTTI publishes no formal licence grant, so the basis for redistributing the AACT-derived portion is that its content is US Government registry data outside copyright, plus CTTI's own encouragement to use it. That is an assessment from published terms, not legal advice.

⚠️ What was removed, and why

The upstream repository builds this graph from more sources than are published here. Two were excluded because their terms do not permit redistribution:

Removed Why Nodes
AdverseEvent Every record is MedDRA-coded (source_vocabulary: "MedDRA"). MedDRA is licensed by ICH/IFPMA on a paid subscription; its terminology may not be redistributed without one. FDA publishing FAERS does not transfer MedDRA's rights. 145,711
Drug Every record carries a drugbank_id. DrugBank has tiered terms, some of which prohibit redistribution outright. 5,256

150,967 nodes (1.9%) and 11,448,933 incident edges (42%) were removed. The edge count falls far more than the node count because adverse-event reporting is dense — each trial reports many events. The REPORTED and CODED_AS_DRUG edge types are therefore absent entirely.

No .sgsnap snapshot is shipped with this dataset, unlike the others in this organisation. The snapshot still contains the MedDRA and DrugBank records, so publishing it would undo the exclusion.

If you need adverse-event or drug data, obtain it from MedDRA and DrugBank directly under their own terms, and rebuild with the ETL in the repository.

Files

Nodes carry an id; edges reference those ids as src and tgt.

nodes/

File Rows Columns
outcome.parquet 3,564,582 id, description, measure, time_frame, trial_nct_id, type
armgroup.parquet 1,055,533 id, label, trial_nct_id, type
site.parquet 1,029,229 id, city, country, facility
publication.parquet 750,114 id, pmid, reference_type, title
clinicaltrial.parquet 575,778 id, nct_id, title, official_title, brief_summary, phase, overall_status, study_type, enrollment, start_date, completion_date, primary_completion_date, has_results, why_stopped, last_updated
intervention.parquet 472,275 id, description, name, type
condition.parquet 125,689 id, name
sponsor.parquet 49,519 id, class, name
meshdescriptor.parquet 6,016 id, name

edges/

File Rows Connects
measures.parquet 3,564,582 ClinicalTrial → Outcome
conducted_at.parquet 3,409,901 ClinicalTrial → Site
coded_as_mesh.parquet 2,623,299 Condition → MeSHDescriptor
uses.parquet 1,282,300 ClinicalTrial → Intervention
has_arm.parquet 1,055,533 ClinicalTrial → ArmGroup
studies.parquet 1,025,129 ClinicalTrial → Condition
published_in.parquet 1,021,552 ClinicalTrial → Publication
tests.parquet 973,353 ArmGroup → Intervention
sponsored_by.parquet 575,778 ClinicalTrial → Sponsor

Usage

from datasets import load_dataset

trials = load_dataset("VaidhyaMegha/clinicaltrials-kg", "clinicaltrial", revision="v1.0")
print(trials["train"].num_rows)      # 575778

Parquet reads well with anything columnar:

import pyarrow.parquet as pq
t = pq.read_table("nodes/clinicaltrial.parquet", columns=["nct_id", "phase", "overall_status"])
// Sponsors running the most trials
MATCH (t:ClinicalTrial)-[:SPONSORED_BY]->(s:Sponsor)
RETURN s.name, count(t) AS trials ORDER BY trials DESC LIMIT 5

// Conditions studied across the most countries — three hops, and the reason
// this is a graph rather than a set of tables
MATCH (c:Condition)<-[:STUDIES]-(t:ClinicalTrial)-[:CONDUCTED_AT]->(site:Site)
RETURN c.name, count(DISTINCT site.country) AS countries, count(DISTINCT t) AS trials
ORDER BY countries DESC LIMIT 10

Verification

  • Node and edge totals reconcile against the snapshot header: 150,967 dropped + 7,628,735 written = 7,779,702; 11,448,933 dropped + 15,531,427 written = 26,980,360.
  • 0 dangling edges — every src and tgt resolves to a node in this dataset.
  • 0 orphan nodes — despite removing 42% of edges, no node was left isolated.
  • Distributions match the public registry: 439,465 interventional vs 134,313 observational (~76% interventional), and the highest-volume sponsors come out as Assiut University, Cairo University, GlaxoSmithKline, the National Cancer Institute and AP-HP — which is what ClinicalTrials.gov itself shows.

Limitations

  • A 2026-04-02 snapshot, not a live mirror. ClinicalTrials.gov changes daily; NLM's terms require this to be stated. For current data go to the registry or AACT.
  • No adverse events and no drug normalisation — see What was removed above. Any analysis of trial safety outcomes is out of scope for this dataset.
  • Text fields are as-registered. Titles, summaries and outcome measures are sponsor-written free text, with the inconsistency that implies.
  • Sites are facility strings, not geocoded or reconciled to any institution registry.
  • Conditions and interventions are strings too; CODED_AS_MESH gives partial normalisation for conditions only.
  • Registry data reflects what sponsors registered, which is not always what was conducted or published.

Not medical advice, and not a substitute for the official registry record.

Citation

Clinical Trials Knowledge Graph, v1.0 (7,628,735 nodes, 15,531,427 edges).
Built with Samyama Graph. https://huggingface.co/datasets/VaidhyaMegha/clinicaltrials-kg
ETL: https://github.com/samyama-ai/clinicaltrials-kg
Source data: ClinicalTrials.gov via the AACT database, Clinical Trials Transformation
             Initiative (CTTI), https://aact.ctti-clinicaltrials.org/
             Courtesy of the U.S. National Library of Medicine.
Snapshot date: 2026-04-02

The three pieces

Piece Where
Code — ETL, schema, loaders github.com/samyama-ai/clinicaltrials-kg
Data — this dataset, and the registry it derives from here, and aact.ctti-clinicaltrials.org
Graph — rebuild from these Parquet files with the ETL (no snapshot shipped — see above)
Downloads last month
41